CORAL GABLES, Fla. — October 7, 2025 — Leads & Copy — Relmada Therapeutics, Inc. (Nasdaq: RLMD) has appointed Max Kates, MD, Associate Professor of Urology and Oncology at Johns Hopkins University School of Medicine, to its Clinical Advisory Board (CAB) to support the development of NDV-01 for non-muscle invasive bladder cancer (NMIBC).
The company intends to initiate the Phase 3 program for NDV-01 in H1 2026.
Raj Pruthi, MD, Chief Medical Officer-Urology, Relmada, said Dr. Kates’ experience chairing the Phase 3 BRIDGE trial and leading other studies will be invaluable. Dr. Kates added that initial safety and efficacy data for NDV-01 underscores the benefit of sustained release formulation of Gem/Doce and that he is eager to contribute his expertise to the pivotal program.
Dr. Kates is a clinician-scientist in bladder cancer with one of the largest surgical practices in the U.S. He serves as chair of the Phase 3 EA8212 BRIDGE Trial and has been the Principal Investigator on numerous studies evaluating new treatments for NMIBC.
NDV-01 is a sustained-release formulation of gemcitabine and docetaxel (Gem/Doce) in development for NMIBC, designed to enable bladder retention and gradual drug release over 10 days.
Relmada Therapeutics is focused on developing therapies for oncology-related and central nervous system conditions.
Contact: Brian Ritchie, LifeSci Advisors, britchie@lifesciadvisors.com; Corporate Communications, media@relmada.com
Source: Relmada Therapeutics, Inc.
